Ovarian Cancer Coverage from Every Angle

Recent News

Identifying a Novel Pathway to Platinum Resistance in Ovarian Cancer
Novel Adenovirus Plus Chemotherapy for Platinum-Resistant Ovarian Cancer
Mirvetuximab Soravtansine Versus Chemotherapy in Platinum-Resistant Ovarian Cancer
NCRI Conference: Early Testing for Levels of CA125 in Diagnosing Ovarian Cancer
Gift of $5M From Leonard A. Lauder to Advance Research in Ovarian Cancer
Does Trametinib Treatment Improve Outcomes in Rare Ovarian Cancer Subtype?
ESMO 2019: Activity of Cediranib Plus Olaparib in Platinum-Resistant Ovarian Cancer
Niraparib Approved by FDA for HRD-Positive Advanced Ovarian Cancer
ESMO 2019: ATR Inhibitor Plus Gemcitabine in High-Grade Serous Ovarian Cancer
ESMO 2019: Olaparib Plus Bevacizumab as Maintenance Therapy for Ovarian Cancer
ESMO 2019: PARP Inhibitor of Benefit in Newly Diagnosed Advanced Ovarian Cancer
ESMO 2019: Adding Veliparib to Front-Line Treatment of High-Grade Serous Carcinoma
Insurance and Mortality in Ovarian and Other Cancers
FAK Signaling and Chemotherapy Resistance in Ovarian Cancer
FDA Grants Accelerated Approval of Pembrolizumab Plus Lenvatinib in Advanced Endometrial Carcinoma
Case Study of Ovarian Mature Teratoma Examines Rare Tumor-to-Tumor Metastasis
Report of Progressive Multifocal Leukoencephalopathy After Platinum-Based Therapy for Ovarian Cancer
Patient-Physician Communication Among Women With Lynch Syndrome
Consequences of Restricting Hospital Choices for Ovarian Cancer Surgery
ALLOCATE Trial: Is Targeted Molecular Profiling Useful in Treating Ovarian Cancer?
Temozolomide Analog Under Study in Treatment of Ovarian Cancer
Olaparib Monotherapy for Ovarian Cancer Evaluated in SOLO3 Trial
Mirvetuximab Soravtansine Plus Bevacizumab in Platinum-Resistant Ovarian Cancer
ESHRE 2019: Assisted Reproductive Technology and Long-Term Risk of Ovarian Cancer
Addition of Adavosertib to Chemotherapy in Platinum-Resistant Ovarian Cancer
Paclitaxel Combination Therapies for Gynecologic Carcinosarcoma
Priority Review of Niraparib in Advanced Ovarian Cancer Granted by FDA
ASCO 2019: Dose-Ranging Study of IMGN853 With Gemcitabine in Ovarian Cancer
NCCN Research Collaboration in Advanced Ovarian Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.